Status: Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).
Participants needed: 420
Trial details
Phase: Phase 3Age: 18-18Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Oct 6, 2026Locations: 44
Eligibility criteria
Documented diagnosis of CLL/SLL with genomic features defined by unmutated IGHV. [+6]
Suspected or confirmed transformation of CLL/SLL to a more aggressive form of ly... [+11]